Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents

被引:0
|
作者
Luo, Y
Rockow-Magnone, SK
Joseph, MK
Bradner, J
Butler, CC
Tahir, SK
Han, EKH
Ng, SC
Severin, JM
Gubbins, EJ
Reilly, RM
Rueter, A
Simmer, RL
Holzman, TF
Giranda, VL
机构
[1] Abbott Labs, Canc Res Pharmaceut Prod Div, Dept 47S AP9A, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Canc Res Pharmaceut Prod Div, Dept 4N6 AP9, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Adv Technol Pharmaceut Prod Div, Dept 4MD AP10, Abbott Pk, IL 60064 USA
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
关键词
G2; abrogation; Chkl; UCN01; staurosporine; chemotherapy sensitization;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Chkl is a checkpoint gene that is activated after DNA damage, It phosphorylates and inactivates Cdc25C at the late G2 phase. The inactivation of Cdc25C and consequently, the inactivation of Cdc2, are required for the G2 arrest induced by DNA damage. Methods: We treated 184B5 cell line and its E6 transformed cell lines with adriamycin in the presence of staurosporine or UCNO1 and examined induced a p53 and p21 response as well as a G1 arrest in 184B5 cells, but not in its E6 transformed cells. Staurosporine or UCNO1 abrogated the G2 arrest induced by adriamycin in both cell lines. In addition staurosporine or UCNO1 specifically sensitized p52 incompetent cells to adriamycin. Conclusion: G2/M checkpoint abrogators can potentially enhance the cytotoxic effect of conventional chemotherapeutic reagents specifically to tumor cells.
引用
收藏
页码:23 / 28
页数:6
相关论文
共 50 条
  • [21] Etoposide radiosensitizes p53-defective cholangiocarcinoma cell lines independent of their G2 checkpoint efficacies
    Hematulin, Arunee
    Meethang, Sutiwan
    Utapom, Kitsana
    Wongkham, Sopit
    Sagan, Daniel
    ONCOLOGY LETTERS, 2018, 15 (03) : 3895 - 3903
  • [22] p53 checkpoint-defective cells are sensitive to X rays, but not hypoxia
    Denko, NC
    Green, SL
    Edwards, D
    Giaccia, AJ
    EXPERIMENTAL CELL RESEARCH, 2000, 258 (01) : 82 - 91
  • [23] Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling
    Christoforos G. Thomas
    Anders Strom
    Karolina Lindberg
    Jan-Ake Gustafsson
    Breast Cancer Research and Treatment, 2011, 127 : 417 - 427
  • [24] Checkpoint abrogation in G2 compromises repair of chromosomal breaks in ataxia telangiectasia cells
    Terzoudi, GI
    Manola, KN
    Pantelias, GE
    Iliakis, G
    CANCER RESEARCH, 2005, 65 (24) : 11292 - 11296
  • [25] Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling
    Thomas, Christoforos G.
    Strom, Anders
    Lindberg, Karolina
    Gustafsson, Jan-Ake
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (02) : 417 - 427
  • [26] ATR inhibition promotes IFN signaling via G2 checkpoint abrogation in irradiated human cancer cells
    Mariampillai, A. Eek
    Hauge, S.
    Oynebraten, I.
    Rodland, G. E.
    Corthay, A.
    Syljuasen, R. G.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S219 - S220
  • [27] The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation
    Kupfer, GM
    DAndrea, AD
    BLOOD, 1996, 88 (03) : 1019 - 1025
  • [28] Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint
    Zhu, WG
    Chen, YF
    Dutta, A
    MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (16) : 7140 - 7150
  • [29] Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
    Kalli Koniaras
    Andrew R Cuddihy
    Helen Christopoulos
    Annette Hogg
    Matthew J O'Connell
    Oncogene, 2001, 20 : 7453 - 7463
  • [30] Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
    Koniaras, K
    Cuddihy, AR
    Christopoulos, H
    Hogg, A
    O'Connell, MJ
    ONCOGENE, 2001, 20 (51) : 7453 - 7463